Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

por Sutton, Kenneth C, De Vente, Jerome, Leblanc, Roger, Dejesus, Edwin, Smith, Graham, Mills, Anthony, Baril, Jean-Guy, St. Clair, Marty, Stancil, Britt S, Vandermeulen, Kati, Spreen, William R
Publicado 2022

Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy

por Mills, Anthony, Richmond, Gary J., Newman, Cheryl, Osiyemi, Olayemi, Cade, Jerry, Brinson, Cynthia, De Vente, Jerome, Margolis, David A., Sutton, Kenneth C., Wilches, Viviana, Hatch, Sarah, Roberts, Jeremy, McCoig, Cynthia, Garris, Cindy, Vandermeulen, Kati, Spreen, William R.
Publicado 2022

Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study

por Smith, Graham H R, Henry, W Keith, Podzamczer, Daniel, Masiá, Maria Del Mar, Bettacchi, Christopher J, Arasteh, Keikawus, Jaeger, Hans, Khuong-Josses, Marie-Aude, Montes-Ramírez, Maria Luisa, Stellbrink, Hans-Jürgen, Yazdanpanah, Yazdan, Richmond, Gary J, Sutton, Kenneth C, Zhang, Feifan, McCoig, Cynthia C, St Clair, Marty H, Vandermeulen, Kati, Van Solingen-Ristea, Rodica, Smith, Kimberly Y, Margolis, David A, Spreen, William R
Publicado 2021